308 related articles for article (PubMed ID: 34481841)
1. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers.
Gudikote JP; Cascone T; Poteete A; Sitthideatphaiboon P; Wu Q; Morikawa N; Zhang F; Peng S; Tong P; Li L; Shen L; Nilsson M; Jones P; Sulman EP; Wang J; Bourdon JC; Johnson FM; Heymach JV
J Biol Chem; 2021 Nov; 297(5):101163. PubMed ID: 34481841
[TBL] [Abstract][Full Text] [Related]
2. Identification of nonsense-mediated mRNA decay pathway as a critical regulator of p53 isoform β.
Cowen LE; Tang Y
Sci Rep; 2017 Dec; 7(1):17535. PubMed ID: 29235495
[TBL] [Abstract][Full Text] [Related]
3. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.
Marcel V; Fernandes K; Terrier O; Lane DP; Bourdon JC
Cell Death Differ; 2014 Sep; 21(9):1377-87. PubMed ID: 24926616
[TBL] [Abstract][Full Text] [Related]
4. Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner.
Li Y; Wu M; Zhang L; Wan L; Li H; Zhang L; Sun G; Huang W; Zhang J; Su F; Tang M; Xiao F
Cell Death Discov; 2022 Sep; 8(1):402. PubMed ID: 36180435
[TBL] [Abstract][Full Text] [Related]
5. Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.
Silden E; Hjelle SM; Wergeland L; Sulen A; Andresen V; Bourdon JC; Micklem DR; McCormack E; Gjertsen BT
PLoS One; 2013; 8(2):e56276. PubMed ID: 23409163
[TBL] [Abstract][Full Text] [Related]
6. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.
Tang Y; Horikawa I; Ajiro M; Robles AI; Fujita K; Mondal AM; Stauffer JK; Zheng ZM; Harris CC
Oncogene; 2013 May; 32(22):2792-8. PubMed ID: 22777358
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.
Li Q; Zhang Y; El-Naggar AK; Xiong S; Yang P; Jackson JG; Chau G; Lozano G
Mol Cancer Res; 2014 Jun; 12(6):901-11. PubMed ID: 24598047
[TBL] [Abstract][Full Text] [Related]
9. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
10. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
11. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.
Oh L; Hainaut P; Blanchet S; Ariffin H
BMC Cancer; 2020 Feb; 20(1):110. PubMed ID: 32041553
[TBL] [Abstract][Full Text] [Related]
13. Regulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways.
Barbier J; Dutertre M; Bittencourt D; Sanchez G; Gratadou L; de la Grange P; Auboeuf D
Mol Cell Biol; 2007 Oct; 27(20):7315-33. PubMed ID: 17709397
[TBL] [Abstract][Full Text] [Related]
14. A Novel Role of SMG1 in Cholesterol Homeostasis That Depends Partially on p53 Alternative Splicing.
Li M; Philantrope F; Diot A; Bourdon JC; Thompson P
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805027
[TBL] [Abstract][Full Text] [Related]
15. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.
Guo Y; Wu H; Wiesmüller L; Chen M
Cell Death Dis; 2024 Jun; 15(6):412. PubMed ID: 38866752
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
17. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.
Fernandez K; Serinagaoglu Y; Hammond S; Martin LT; Martin PT
Am J Pathol; 2010 Jan; 176(1):416-34. PubMed ID: 20019182
[TBL] [Abstract][Full Text] [Related]
18. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
19. Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53.
Ji W; Ma J; Zhang H; Zhong H; Li L; Ding N; Jiao J; Gao Z
Mol Med Rep; 2015 Jul; 12(1):691-5. PubMed ID: 25695150
[TBL] [Abstract][Full Text] [Related]
20. SRSF2 Regulation of
Comiskey DF; Montes M; Khurshid S; Singh RK; Chandler DS
Mol Cancer Res; 2020 Feb; 18(2):194-203. PubMed ID: 31662450
[No Abstract] [Full Text] [Related]
[Next] [New Search]
